Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.

AptarGroup, Inc.

ATRNYSE
Wall Street Score · overall investment39/100
$126.51USD$-0.56 (-0.44%)
Company website www.aptar.com
Headquarters265 Exchange Drive, Crystal Lake, IL, 60014, US
Financial statement currencyUSD · no FX conversion applied
Healthcare · Medical - Instruments & Supplies
Price updated todayFinancials updated Oct 1, 2026

ATR · Price history

Price at last available close

$126.51

+$2.06 (+1.66%) 1M

2026-10-27

Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.

Company & revenue

About AptarGroup, Inc.

Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.

Who they are

AptarGroup, Inc. specializes in developing and manufacturing solutions for dispensing, sealing, and advanced material science, catering to a broad spectrum of industries such as beauty, personal care, home care, and the pharmaceutical sector (including prescription drugs, consumer health care, and injectables), alongside the food and beverage markets. Its operations are structured into three key segments: Pharma, Beauty + Home, and Food + Beverage. The Pharma division offers critical components for the pharmaceutical industry, including pumps for nasal allergy remedies, metered dose inhaler valves vital for managing respiratory conditions like asthma and chronic obstructive pulmonary disease (COPD), elastomeric primary packaging for injectables, and sophisticated active material science innovations.

How they make money

AptarGroup generates revenue by designing and manufacturing a broad range of drug delivery, consumer product dispensing, and sealing solutions. The company operates through a global manufacturing footprint, selling its proprietary technologies to customers in the pharmaceutical, beauty, personal care, home care, and food and beverage markets.

Products & services

Aerosol valves, pumps, closures, drug delivery systems, and specialized dispensing technologies for pharmaceutical and consumer goods.

Brands & revenue mix

No separate brand or brand-level revenue disclosure was confirmed in the reviewed sources. This does not mean the company has no brands.

Product / operating segments

No reconciled product or operating-segment revenue breakdown is available for the current research period. Company-wide revenue remains separate from segment disclosure.

Geographic revenue

No reconciled geographic revenue breakdown was confirmed for the current research period.

Customer types

  • Pharmaceutical companiesSource
  • Beauty and personal care companiesSource
  • Food and beverage companiesSource

Customer concentration

The company has approximately 5,000 customers, with no single customer or group of affiliated customers accounting for greater than 4% of 2025 Net Sales.

Suppliers, materials & equipment

  • Raw material and component suppliers — The company relies on various third-party suppliers for resins, metals, and other raw materials used in manufacturing; specific supplier names are not disclosed.Source

Strengths

  • Global manufacturing footprintSource
  • Diversified customer baseSource

Risks

  • Fluctuations in raw material costsSource
  • Global economic and geopolitical instabilitySource

Wall Street Score

Overall investment score · Quality, value, risk and opportunity

39

Poor

PoorElite

View category scores →

Company Quality

How good is the actual business—regardless of today’s stock price?

65

Fair

Financial Strength

50

Business Quality / Moat

65

Management

90

Growth Quality

48

Risk / Durability

88

Weak Company · Expensive Stock

Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.

Opportunity

Opportunity Score · How does the current price compare with estimated value?

32

Avoid

Based on current valuation, company quality, recent trends, and available market signals.

View score details →

Model Outlook

12-month model · What does the model think happens next?

42/100

Building Historical Record

Model Score 42/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.

Probability unavailable — the model has not produced a calibrated probability yet.

Click for full breakdown →

WSS View

The quick read

The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.

At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.

The model outlook is currently cautious.

What we like
  • •Recent buyback activity is present
What to watch
  • •Valuation is a weaker part of the current profile
  • •Revenue fundamentals are weak
  • •Debt / balance-sheet profile needs attention

Company-specific research

Questions worth answering for ATR

Research inputs 100% complete

These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.

  • •Can ATR maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
  • •Is ATR's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
  • •Is ATR's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • •What future growth or profitability would be needed to justify ATR's current valuation?
Business analysis: 15 days ago · Fresh

Essential Investment Snapshot

Wall Street Score

39

0–100 · Weak

Opportunity Score

32

0–100 · Poor

Market Cap

$8.04B

P/E Ratio

21.6

EPS

$5.60

52-Week High

$146.91

52-Week Low

$103.23

Beta

0.38

Intrinsic Value

$96.55

Analyst Target

$160.00

Shares Outstanding

66.7M

Total Revenue

$3.93B

Total Debt

$1.43B

Dividend Yield (TTM)

1.14%

View dividend history

Liquidation Value / Share

$40.08

Estimated net asset value per share

Dividend / Share (TTM)

$1.44

Trailing 12 months by ex-date; not a forecast

Momentum & Volatility Signals

Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.

0–100 market signals
Momentum
56/ 100
-1 pts / 5d

Neutral / mixed momentum

5D +0.6% · 20D +2.6% · RSI 69 · Price vs 20D avg +3.0%
Volatility
18/ 100
+3 pts / 5d

Low movement

20D realized vol 18.6% · 60D 16.0% · Acceleration 1.16x
Momentum = Where is it going?

A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.

Volatility = How violently is it moving?

A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.

Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.

Notices for ATR

Detected from reported data — verify before acting.

Dividend history reported

Dividend payments are recorded. Review the dates and regular/special classification below; past payments do not guarantee future dividends.

Historical repurchase activity

Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.

Community Sentiment

0 active · 0 total calls
0% Bullish (0) 0% Bearish (0)

No personal call yet on ATR.

Potential upside factors

  • +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
  • +Global manufacturing footprint.
  • +Diversified customer base.
  • +Positive free cash flow may provide capacity to invest in growth.

Potential downside factors

  • −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Instruments & Supplies industry.
  • −Fluctuations in raw material costs.
  • −Global economic and geopolitical instability.

These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.

Create a free account to make a call.

Scores

Click any score for full breakdown
Wall Street Score
Weak39/ 100
Weak (0–50)Fair (51–71)Strong (72+)

Poor

39

Tap for breakdown →

Weak

46

Debt Cost3.4%
Debt Reduction YoY-42.3%
Debt / Equity0.57x

Tap for breakdown →

Poor

21

Revenue YoY4.1%
Revenue CAGR4.1%
Net Margin9.2%

Tap for breakdown →

Fair

53

Asset Growth YoY18.5%
Liquidation/Share$40.08
Net Assets/MCap0.48x

Tap for breakdown →

Poor

37

Earnings Yield4.7%
Buyback Yield1.9%
Debt Cost3.4%

Tap for breakdown →

Elite

90

ROIC10.6%
ROE13.8%
ROA7.1%

Tap for breakdown →

Fair

65

EPS Growth10.4%
FCF/Share Growth5.9%
Rev/Share Growth5.1%

Tap for breakdown →

Poor

16

Intrinsic Value$96.55
Value Reference$57.93
MOS-31.0%

Tap for breakdown →

Weak

48

Revenue21
Moat65
Valuation16

Tap for breakdown →

Poor

0

MOS %-31.0%
Value Reference$57.93
Deep Discount Reference$38.62

Tap for breakdown →

Poor

37

Interest Coverage9.7x
ROIC10.6%
FCF Yield3.9%

Tap for breakdown →

Poor

35

Financial37
Valuation16
Debt46

Tap for breakdown →

Fair

59

Survival Years0.9 yrs
Current Ratio1.62x
FCF Margin7.9%

Tap for breakdown →

Was this stock page easy to understand?

One click helps us improve the research experience. This is not tied to an investment decision.

Score Changes

7 historical score records available

Previous Score

39

Sep 9, 2026

Change

+0.1

points

Current Score

39

Oct 1, 2026

Category Changes

Revenue+0.3
Debt0
Assets+0.4
Capital+1.0
Management0
Moat-0.1
Valuation0
Buffett+0.1

ATR increased 0.1 points because overall fundamentals improved.

Projected Score

Projected Score

34

Projected Change

-4.8 points

Preliminary comparable-period financial changes suggest decline of approximately 4.8 points. This is a projected estimate, not the official WallStreetScore.

Price vs. Value

Overvalued

Current Price

$126.51

Model Intrinsic Value

$96.55

Difference

+$29.96

+31.0% vs IV

Margin of Safety

-31.0%

UndervaluedFair ValueOvervalued
Value Reference: $57.93
Deep Discount Reference: $38.62

Financial Charts

Revenue

201420152016201720182019202020212022202320242025$0$950M$1.9B$2.9B$3.8B

Additional Metrics

Operating Cash Flow

201520172019202120232025$0$200M$400M$600M$800M

Total Debt

201520172019202120232025$0$400M$800M$1.2B$1.6B

Total Assets

201520172019202120232025$0$1.5B$3.0B$4.5B$6.0B

Net Margin %

No data
Monetary values in USD. Share counts in raw units.

Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.

Line ItemTTM2025202420232022202120202019201820172016
Revenue$3.93B$3.78B$3.58B$3.49B····························
Cost of Revenue$2.82B$2.66B$2.23B$2.22B····························
Gross Profit$1.11B$1.12B$1.36B$1.26B····························
Research & Development$325.3M$105.1M$0.00$0.00····························
SG&A Expenses$634.8M$499.9M$582.2M$565.8M····························
Operating Expenses$625.0M$605.0M$859.0M$859.4M····························
EBITDA$822.2M$831.5M$777.4M$663.8M····························
Operating Income$486.5M$512.3M$496.5M$404.0M····························
Interest Expense$63.5M$52.7M$43.9M$40.4M····························
Income Before Tax$454.5M$491.4M$469.8M$374.8M····························
Income Tax Expense$91.6M$98.9M$95.6M$90.6M····························
Net Income$362.5M$392.8M$374.5M$284.5M····························
Basic EPS$5.60$5.97$5.65$4.34····························
Basic Shares63.84M65.74M66.33M65.62M····························
Diluted Shares64.50M66.72M67.69M66.91M····························
Upgrade to Premium for up to 10 annual periods, where available.
Upgrade to Premium

Earnings Summary

Estimated earnings date:Oct 29, 2026
Estimated EPS: $1.48Estimated revenue: $982.8M
Jun 30, 2026Q2FY2026

Revenue

$1.03B

Estimate unavailable.

Revenue Beat/Miss

Not available (no estimate stored)

EPS

$1.36

Estimate unavailable.

EPS Beat/Miss

Not available (no estimate stored)

Debt Change

+25.6%

Cash Change

+17.7%

Margin Change

-3.0 pp

Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.

Financial Changes Since Prior Period

What Improved

  • Cash position grew

What Weakened

  • Margins contracted
  • Debt increased

Potential Score Impact

Positive indicators included revenue growth, cash levels. Pressure indicators included EPS growth, debt levels, net income margin. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.

Stored Earnings Analysis

Revenue increased 6.3%. EPS declined 18.6%. Cash increased 17.7%. Total debt increased 25.6%. Net income margin declined by 3.0 percentage points.

Earnings-Call Transcript

Earnings-call transcript analysis is not currently available.

These results may influence future scores when the next evaluation is completed.

Upgrade to Premium to unlock all earnings history.View plans
Earnings data: 120 days ago · Stale

Insider Activity

Guru / Smart Money

Guru Score

Smart Money

Number of Gurus

Total Guru Value

Avg Portfolio Weight

Largest Holder

Largest Holder %

New Positions

Increased Positions

Reduced Positions

Exited Positions

Net Guru Sentiment

Loading data...

Short Interest

Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.

Dividend History

Log in to view dividend history.

Conservative Projected Values

3 Years

$———.——

Premium

5 Years

$———.——

Premium

10 Years

$———.——

Premium

Conservative Projection Rate

——%

Premium

Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.

Conservative Projected Values

Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.

Start 7-Day Free Trial

Historical Outperformance Record

Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.

Start 7-Day Free Trial

Historical Trends

7 historical records
Jul 19, 26Jul 23, 26Aug 11, 26Sep 1, 26Sep 8, 26Sep 9, 26Oct 1, 260255075100

Historical Score Chart

3 of 7 records shown
3 historical score records are shown. Start your seven-day free trial to unlock 4 more records and the complete score history.Start Free Trial

Wall Street Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Debt Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Revenue Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Asset Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Capital Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Management Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Moat Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Valuation Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Buffett Score

Sep 8, 26Sep 9, 26Oct 1, 260255075100

Intrinsic Value

Sep 8, 26Sep 9, 26Oct 1, 26$94.00$95.00$96.00$97.00$98.00

Value Reference

Sep 8, 26Sep 9, 26Oct 1, 26$55.00$56.00$57.00$58.00$59.00

Margin of Safety %

Sep 8, 26Sep 9, 26Oct 1, 26-0.3%-0.3%-0.3%-0.3%-0.3%

Related Companies

Medical - Instruments & Supplies

NEPH

Nephros, Inc.

66Fair
$3.52View

PDEX

Pro-Dex, Inc.

65Fair
$59.40View

LMAT

LeMaitre Vascular, Inc.

58Fair
$83.79View

ZJYL

Jin Medical International Ltd.

55Fair
$1.94View

RMD

ResMed Inc.

55Fair
$246.69View

NNNN

Anbio Biotechnology Class A Ordinary Shares

51Fair
$3.73View

News

Rumor Mill · ATR

Corporate developments & opportunities

Explore market →

No reviewed developments match this filter.

Evidence credibility is not a forecast of stock performance. Rumor Mill is separate from the WSS score.

Related Stock Research

Continue researching this company with related Wall Street Score rankings and investing guides.

Highest Wall Street Score stocksBest growth stocksBest healthcare stocksHow Wall Street Score worksHow to analyze a stockUnderstanding financial healthIntrinsic value guide

Score Alerts

Premium unlocks alerts when a score rises, falls, or reaches your target price.

Start 7-Day Free Trial

Portfolio Score

Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.

Start 7-Day Free Trial